20 related articles for article (PubMed ID: 38483062)
1. The importance of combined HPV and CINtec® PLUS genotyping testing for p16 in women with cervical squamous cell carcinoma.
Voidăzan TS; Budianu MA; Cotoi OS; Turdean SG
Rom J Morphol Embryol; 2024; 65(1):99-105. PubMed ID: 38527989
[TBL] [Abstract][Full Text] [Related]
2. High-Risk HPV CISH Detection in Cervical Biopsies with Weak and/or Focal p16 Immunohistochemical Positivity.
Cabibi D; Giannone AG; Quattrocchi A; Lo Coco R; Formisano E; Porcasi R; Benfante V; Comelli A; Capra G
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791395
[TBL] [Abstract][Full Text] [Related]
3. p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.
Pirtea L; Secosan C; Margan M; Moleriu L; Balint O; Grigoras D; Sas I; Horhat F; Jianu A; Ilina R
Bosn J Basic Med Sci; 2019 Nov; 19(4):336-341. PubMed ID: 29924960
[TBL] [Abstract][Full Text] [Related]
4. P16/Ki-67 Dual Staining in Positive Human Papillomavirus DNA Testing for Predictive Diagnosis of Abnormal Cervical Lesions in Northeastern Thai Women.
Aromseree S; Wongjumpa W; Ekalaksananan T; Temtanakitpaisan A; Kleebkaow P; Srisathaporn S; Tongchai P; Pientong C
Asian Pac J Cancer Prev; 2022 Oct; 23(10):3405-3411. PubMed ID: 36308365
[TBL] [Abstract][Full Text] [Related]
5. Improved abnormal Pap smear triage using cervical cancer biomarkers.
Killeen JL; Dye T; Grace C; Hiraoka M
J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145
[TBL] [Abstract][Full Text] [Related]
6. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
[TBL] [Abstract][Full Text] [Related]
7. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria.
Sroczynski G; Esteban E; Widschwendter A; Oberaigner W; Borena W; von Laer D; Hackl M; Endel G; Siebert U
Int J Cancer; 2020 Aug; 147(4):1131-1142. PubMed ID: 31872420
[TBL] [Abstract][Full Text] [Related]
8. Management of high-risk HPV-positive women for detection of cervical (pre)cancer.
Luttmer R; De Strooper LM; Steenbergen RD; Berkhof J; Snijders PJ; Heideman DA; Meijer CJ
Expert Rev Mol Diagn; 2016 Sep; 16(9):961-74. PubMed ID: 27459506
[TBL] [Abstract][Full Text] [Related]
9. Correlation between high-risk HPV infection and p16/Ki-67 abnormalities in Pap samples in a South Eastern Europe cohort.
Shalaby NA; Tudorescu-Morjan C; Manole CG; Iacata AA; Popovici ML; Grecu LI; Curici A
J Med Virol; 2024 Mar; 96(3):e29524. PubMed ID: 38483062
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of p16/Ki-67 immunocytochemistry for triage of women with abnormal Papanicolaou test in cervical cancer screening: a systematic review and meta-analysis.
Chen CC; Huang LW; Bai CH; Lee CC
Ann Saudi Med; 2016; 36(4):245-51. PubMed ID: 27478909
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]